What is driving the pre-market activity in ALDEI.PA stock?

Pre-market activity stems from heavy trading volume of **13,014,939** shares and news sensitivity in biotech. Clinical trial milestones, partner updates or liquidity shifts often trigger large moves in a microcap like Deinove.

How does Deinove’s balance sheet affect ALDEI.PA stock valuation?

Deinove reports **€0.1344** cash per share and negative book value (**-€0.4556**). Limited revenues and negative EPS mean valuation is forward-looking and tied to clinical success and partnerships rather than current profits.

What price target does Meyka AI give for ALDEI.PA stock?

Meyka AI's forecast model projects a baseline target of **€0.0600**, implying **+126.42%** from **€0.0265**. This is a model projection and not a guarantee; outcomes depend on trials and funding.

Is ALDEI.PA stock a buy for short-term traders?

Short-term trades may profit from high intraday volume, but risk is high due to microcap volatility and thin liquidity. Use tight risk controls, small size, and limit orders when trading ALDEI.PA stock.

EU Stocks

ALDEI.PA Deinove SA EURONEXT pre-market: €0.0265 13.01M shares active

ByDanny Kontos January 21, 2026January 21, 2026

ALDEI.PA stock is trading pre-market on EURONEXT at €0.0265 with 13,014,939 shares reported, making Deinove SA one of the most active small caps in Europe today. Volume is more than double average, at a relative volume of 2.17, pushing the price inside a tight intraday range (€0.0231–€0.0321). Investors are watching biotech catalysts and balance-sheet signals. We use company data, sector context and Meyka AI-powered market analysis to explain why trading activity is elevated and what to watch next.